EA201890578A1 - Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли - Google Patents
Предотвращение, лечение и снижение (персистирующей) посттравматической головной болиInfo
- Publication number
- EA201890578A1 EA201890578A1 EA201890578A EA201890578A EA201890578A1 EA 201890578 A1 EA201890578 A1 EA 201890578A1 EA 201890578 A EA201890578 A EA 201890578A EA 201890578 A EA201890578 A EA 201890578A EA 201890578 A1 EA201890578 A1 EA 201890578A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- post
- traumatic headache
- persistent
- prevention
- reduction
- Prior art date
Links
- 206010036313 Post-traumatic headache Diseases 0.000 title abstract 3
- 230000002085 persistent effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232343P | 2015-09-24 | 2015-09-24 | |
| US201662375825P | 2016-08-16 | 2016-08-16 | |
| PCT/IB2016/055720 WO2017051385A1 (en) | 2015-09-24 | 2016-09-23 | Preventing, treating, and reducing (persistent) post-traumatic headache |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890578A1 true EA201890578A1 (ru) | 2018-12-28 |
Family
ID=57121460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890578A EA201890578A1 (ru) | 2015-09-24 | 2016-09-23 | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170088612A1 (enExample) |
| EP (1) | EP3353202B1 (enExample) |
| JP (2) | JP2018532728A (enExample) |
| KR (2) | KR20180058777A (enExample) |
| CN (1) | CN108473560A (enExample) |
| AU (2) | AU2016325738A1 (enExample) |
| CA (1) | CA2999809A1 (enExample) |
| EA (1) | EA201890578A1 (enExample) |
| ES (1) | ES2846878T3 (enExample) |
| HK (1) | HK1258385A1 (enExample) |
| IL (1) | IL258008A (enExample) |
| MX (1) | MX2018003713A (enExample) |
| WO (1) | WO2017051385A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG194973A1 (en) | 2011-05-20 | 2013-12-30 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| US9745373B2 (en) | 2011-05-20 | 2017-08-29 | Alderbio Holdings Llc | Anti-CGRP compositions and use thereof |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| KR20230107902A (ko) | 2014-02-05 | 2023-07-18 | 머크 샤프 앤드 돔 엘엘씨 | Cgrp-활성 화합물에 대한 정제 제제 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| KR20220031944A (ko) | 2016-09-23 | 2022-03-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
| US12398209B2 (en) * | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
| AU2020206241A1 (en) | 2019-01-08 | 2021-08-26 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-CGRP antibodies |
| EP3956025A1 (en) * | 2019-04-18 | 2022-02-23 | Allergan Sales, LLC | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| CN116096399A (zh) | 2020-06-03 | 2023-05-09 | 米奥托克斯有限责任公司 | 用于治疗偏头痛病症的区带性和靶向方法和用途 |
| AU2021319090A1 (en) | 2020-07-29 | 2023-03-02 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2022140537A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704770D0 (sv) * | 1997-12-19 | 1997-12-19 | Astra Ab | New use |
| KR20080068062A (ko) * | 2005-11-14 | 2008-07-22 | 리나트 뉴로사이언스 코퍼레이션 | 칼시토닌 유전자-관련 펩티드에 대해 지시되는 길항제 항체및 그의 사용 방법 |
| US9745373B2 (en) * | 2011-05-20 | 2017-08-29 | Alderbio Holdings Llc | Anti-CGRP compositions and use thereof |
| SG11201403769YA (en) * | 2012-01-10 | 2014-07-30 | Noxxon Pharma Ag | Nucleic acids specifically binding cgrp |
| US8722060B2 (en) * | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
-
2016
- 2016-09-23 US US15/274,331 patent/US20170088612A1/en not_active Abandoned
- 2016-09-23 KR KR1020187011355A patent/KR20180058777A/ko not_active Ceased
- 2016-09-23 JP JP2018515658A patent/JP2018532728A/ja active Pending
- 2016-09-23 WO PCT/IB2016/055720 patent/WO2017051385A1/en not_active Ceased
- 2016-09-23 CA CA2999809A patent/CA2999809A1/en not_active Abandoned
- 2016-09-23 AU AU2016325738A patent/AU2016325738A1/en not_active Abandoned
- 2016-09-23 ES ES16778888T patent/ES2846878T3/es active Active
- 2016-09-23 KR KR1020207008057A patent/KR20200035163A/ko not_active Withdrawn
- 2016-09-23 MX MX2018003713A patent/MX2018003713A/es unknown
- 2016-09-23 CN CN201680068514.8A patent/CN108473560A/zh active Pending
- 2016-09-23 EA EA201890578A patent/EA201890578A1/ru unknown
- 2016-09-23 EP EP16778888.4A patent/EP3353202B1/en active Active
- 2016-09-23 HK HK19100783.0A patent/HK1258385A1/zh unknown
-
2018
- 2018-03-11 IL IL258008A patent/IL258008A/en unknown
-
2019
- 2019-06-11 US US16/437,776 patent/US20200148761A1/en not_active Abandoned
- 2019-09-13 JP JP2019167098A patent/JP2020002172A/ja active Pending
- 2019-11-06 AU AU2019261726A patent/AU2019261726A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/222,737 patent/US20220048986A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170088612A1 (en) | 2017-03-30 |
| US20200148761A1 (en) | 2020-05-14 |
| US20220048986A1 (en) | 2022-02-17 |
| ES2846878T3 (es) | 2021-07-30 |
| IL258008A (en) | 2018-06-28 |
| AU2019261726A1 (en) | 2019-11-28 |
| CA2999809A1 (en) | 2017-03-30 |
| CN108473560A (zh) | 2018-08-31 |
| AU2016325738A1 (en) | 2018-04-12 |
| MX2018003713A (es) | 2018-08-15 |
| WO2017051385A1 (en) | 2017-03-30 |
| HK1258474A1 (en) | 2019-11-15 |
| KR20180058777A (ko) | 2018-06-01 |
| JP2020002172A (ja) | 2020-01-09 |
| JP2018532728A (ja) | 2018-11-08 |
| HK1258385A1 (zh) | 2019-11-08 |
| EP3353202A1 (en) | 2018-08-01 |
| KR20200035163A (ko) | 2020-04-01 |
| EP3353202B1 (en) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890578A1 (ru) | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли | |
| CL2019000760A1 (es) | Tratamiento de migraña refractaria | |
| MX2019003338A (es) | Tratamiento de cefalea en racimos. | |
| MX2024005976A (es) | Un anticuerpo anti-tigit, un anticuerpo anti-pvrig y un anticuerpo anti-pd-1 para usarse en el tratamiento de cancer. | |
| MX2019013072A (es) | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
| MX2021005394A (es) | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
| MX2015004105A (es) | Anticuerpos monoclonales humanos anti-pd-l1 y metodos de uso. | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| MX382549B (es) | Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1. | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| EA201790834A1 (ru) | Молекулы антител к pd-l1 и их применение | |
| MX387530B (es) | Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migraña. | |
| EA201591806A1 (ru) | Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител | |
| CA3174958C (en) | ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| MX2020008122A (es) | Anticuerpos anti-pd-1. | |
| EP4234013A3 (en) | Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3 | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof |